Wright M J, Woodrow G, Umpleby S, Hull S, Brownjohn A M, Turney J H
Wellcome Wing, Leeds General Infirmary, Leeds, UK.
Am J Kidney Dis. 1999 Jul;34(1):36-42. doi: 10.1016/s0272-6386(99)70105-8.
Heparin is the most commonly used anticoagulant for hemodialysis despite potentially serious side effects. Polyethylene glycol-grafted cellulose (PGC) membranes produce less activation of the coagulation cascade than cuprophane membranes. Anecdotally, we found some patients required a surprisingly low level of anticoagulation using these membranes. We compared the anticoagulant requirement of the PGC membrane with that of the cuprophane membrane in this randomized, prospective, crossover study. Sixty-three patients were randomized to treatment using either membrane, and heparin administration was progressively reduced to the lowest dose that prevented visible clotting in excess of that normally encountered. Patients underwent dialysis at this dose for 1 month, after which the heparin requirement and Kt/Vurea (1.162 x ln [urea pre/urea post]) were assessed. This process was then repeated for each patient using the other membrane, and the results were compared. Heparin administration during dialysis was reduced from a mean loading dose of 29.0 +/- 9.4 to 1.5 +/- 3.2 IU/kg for both membranes and a mean maintenance infusion of 14.0 +/- 6.7 to 0.77 +/- 1.6 IU/kg/h for both membranes (both P < 0.0001 v full anticoagulation; no difference between membranes). The Kt/Vurea was not significantly altered. Forty-six patients with PGC and 45 patients with cuprophane membranes underwent dialysis successfully without heparin during dialysis, and the other patients were using considerably reduced doses. Aspirin and warfarin had no effect on the heparin requirement. These results do not support the theory that PGC membranes have a lower anticoagulant requirement than cuprophane membranes; however, they suggest that dialysis can be performed successfully with much smaller anticoagulant doses than are currently in common use.
尽管肝素存在潜在的严重副作用,但它仍是血液透析中最常用的抗凝剂。聚乙二醇接枝纤维素(PGC)膜比铜仿膜产生的凝血级联激活作用更小。根据传闻,我们发现一些患者使用这些膜时所需的抗凝水平低得出奇。在这项随机、前瞻性、交叉研究中,我们比较了PGC膜和铜仿膜的抗凝需求。63名患者被随机分配使用其中一种膜进行治疗,肝素给药量逐渐减少至能防止出现超过正常所见明显凝血的最低剂量。患者以该剂量进行1个月的透析,之后评估肝素需求量和Kt/Vurea(1.162×ln[透析前尿素/透析后尿素])。然后对每位患者使用另一种膜重复此过程,并比较结果。两种膜在透析期间的肝素给药量从平均负荷剂量29.0±9.4降至1.5±3.2 IU/kg,平均维持输注量从14.0±6.7降至0.77±1.6 IU/kg/h(与完全抗凝相比,两者P均<0.0001;两种膜之间无差异)。Kt/Vurea没有显著改变。46名使用PGC膜和45名使用铜仿膜的患者在透析期间成功无需肝素进行透析,其他患者使用的剂量也大幅减少。阿司匹林和华法林对肝素需求量没有影响。这些结果不支持PGC膜比铜仿膜抗凝需求更低的理论;然而,它们表明使用比目前常用剂量小得多的抗凝剂也能成功进行透析。